Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Zhu, Andrew X, Dr, Park, Joon Oh, MD, Ryoo, Baek-Yeol, MD, Yen, Chia-Jui, MD, Poon, Ronnie, MD, Pastorelli, Davide, MD, Blanc, Jean-Frederic, MD, Chung, Hyun Cheol, MD, Baron, Ari D, MD, Pfiffer, Tulio Eduardo Flesch, MD, Okusaka, Takuji, MD, Kubackova, Katerina, MD, Trojan, Jorg, MD, Sastre, Javier, PhD, Chau, Ian, MD, Chang, Shao-Chun, MD, Abada, Paolo B, MD, Yang, Ling, MS, Schwartz, Jonathan D, MD, Kudo, Masatoshi, MD
Published in The lancet oncology (01.07.2015)
Published in The lancet oncology (01.07.2015)
Get full text
Journal Article
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
El-Khoueiry, Anthony B, Dr, Sangro, Bruno, MD, Yau, Thomas, MD, Crocenzi, Todd S, MD, Kudo, Masatoshi, MD, Hsu, Chiun, MD, Kim, Tae-You, MD, Choo, Su-Pin, BMBS, Trojan, Jörg, MD, Welling, Theodore H, MD, Meyer, Tim, MD, Kang, Yoon-Koo, MD, Yeo, Winnie, MD, Chopra, Akhil, MD, Anderson, Jeffrey, MD, dela Cruz, Christine, MD, Lang, Lixin, PhD, Neely, Jaclyn, PhD, Tang, Hao, PhD, Dastani, Homa B, PhD, Melero, Ignacio
Published in The Lancet (British edition) (24.06.2017)
Published in The Lancet (British edition) (24.06.2017)
Get full text
Journal Article
Three late adverse events of choledochoduodenostomy of which the endoscopist should be aware: direct retrograde cholangioscopy is helpful for diagnosis and therapy
Albert, Jörg G., MD, Tal, Andrea, MD, Bechstein, Wolf O., MD, Trojan, Jörg, MD, Schnitzbauer, Andreas, MD
Published in Gastrointestinal endoscopy (01.02.2015)
Published in Gastrointestinal endoscopy (01.02.2015)
Get full text
Journal Article